01801.HK
Innovent Biologics, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 81.60
+0.43%Year over year
Reported trailing growth
- Revenue
- +36.5%
- EBITDA
- +181.5%
- EBIT
- +157.7%
- EPS
- +5.7%
- Free cash flow
- +698.4%
- Operating cash flow
- +592.2%
Forward estimates
Based on analyst estimates
- Revenue
- -30.1%
- EBITDA
- +22.4%
- EPS
- +64.0%
Three-year CAGR
- Revenue
- +42.0%
- EBITDA
- +497.2%
- EBIT
- +197.1%
- Net income
- +959.7%
- EPS
- +926.2%
- Free cash flow
- +2327.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026